In this review:
OReO: Maintenance olaparib rechallenge extends PFS in relapsed disease
PARP inhibitors beyond progression for oligometastatic OC recurrence
First-line olaparib/bevacizumab maintenance confers PFS benefit regardless of age
KELIM prognostic for survival in newly diagnosed advanced OC
Results of dual RAF/MEK and FAK inhibition from FRAME
Real-world single-agent MEK inhibition with trametinib for LGSOC
OCTOVA: Olaparib plus cediranib confers PFS benefit in platinum-resistant disease
Ceralasertib shows anti-tumour activity in ARID1A-deficient advanced solid tumours
ATARI will assess ceralasertib ± olaparib in gynaecological cancers
KEYNOTE-826: pembrolizumab + chemotherapy the new standard for cervical cancer
Please login below to download this issue (PDF)